This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
S&P 500 Touches 3,000 Again: Winning Stocks of IVV ETF
by Sanghamitra Saha
The S&P 500 has rallied 1.2% on May 26, topping the 3,000-mark for the first time since Mar 5.
Here's Why You Should Add Surmodics to Your Portfolio Now
by Zacks Equity Research
Investor confidence is high in Surmodics (SRDX) stock, thanks to solid prospects.
Here's Why You Should Retain Merit Medical (MMSI) for Now
by Zacks Equity Research
Investor confidence is high in Merit Medical (MMSI) stock, thanks to solid prospects.
Allscripts Unit Inks Deal to Boost Veradigm AccelRx Platform
by Zacks Equity Research
This deal is expected to bolster Allscripts' (MDRX) Clinical and Financial Solutions segment.
Is DexCom (DXCM) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (DXCM) Outperforming Other Medical Stocks This Year?
Here's Why You Should Retain Masimo Stock (MASI) For Now
by Zacks Equity Research
Investor confidence remains high in Masimo (MASI) stock, thanks to solid prospects.
Nasdaq ETF (QQQ) Joins $100 Billion Club: 10 Stock Winners
by Sweta Killa
Invesco QQQ (QQQ), which tracks the Nasdaq 100 Index, joined the $100 billion club of AUM last week.
Should iShares Morningstar MidCap Growth ETF (JKH) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for JKH
ESG Stocks Remain Resilient to Virus Slump: 5 Top Picks
by Zacks Equity Research
ESG stocks bear lesser financial risk due to their focus on environment, employees and supply chain. Investment in these companies can return well.
Is DexCom (DXCM) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (DXCM) Outperforming Other Medical Stocks This Year?
DexCom (DXCM) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
DexCom's (DXCM) first-quarter earnings benefit from solid segmental performance.
DexCom (DXCM) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
DexCom (DXCM) delivered earnings and revenue surprises of 340.00% and 14.01%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Quest Diagnostics Grows on New Tests Amid Coronavirus Crisis
by Zacks Equity Research
Quest Diagnostics' (DGX) new COVID-19 tests start adding to its Diagnostic information Services business sales.
Baxter (BAX) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
Baxter's (BAX) first-quarter performance is likely to reflect growth in its six global business units.
Stryker (SYK) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
Stryker's (SYK) first-quarter earnings likely to reflect strong segmental performances by Medsurg and Neurotechnology & Spine.
Why DexCom (DXCM) Might Surprise This Earnings Season
by Zacks Equity Research
DexCom (DXCM) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
AMN Healthcare Inks Deal to Address Healthcare System Needs
by Zacks Equity Research
This partnership is expected to boost AMN Healthcare's (AMN) Other Workforce Solutions segment.
What's in Store for Juniper (JNPR) This Earnings Season?
by Zacks Equity Research
Juniper's (JNPR) first-quarter 2020 performance is likely to have benefited from changes to its go-to-market structure to better align sales strategies with each of the core customer verticals.
Optical & Display Units to Hurt Corning's (GLW) Q1 Earnings
by Zacks Equity Research
Headwinds in the Optical Communications and Display Technologies business segments are likely to get reflected in Corning's (GLW) first-quarter 2020 results.
Edwards Lifesciences (EW) Beats on Q1 Earnings, Cuts '20 View
by Zacks Equity Research
Amid the coronavirus impact on sales, Edwards Lifesciences (EW) witnesses growth in TAVR procedures led by strong therapy adoption across all geographies, particularly in the United States.
Merit Medical (MMSI) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Merit Medical Systems (MMSI) has registered an increase in revenues at both its key operating segments in Q1
ABIOMED (ABMD) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
ABIOMED's (ABMD) fiscal fourth-quarter performance is likely to reflect growth in Impella product line.
3 Medical Product Stocks Set to Beat This Earnings Season
by Urmimala Biswas
Here we discuss three medical product stocks that are due to report soon and are likely to beat estimates on earnings, riding on a host of factors.
What's in Store for IDEXX Laboratories (IDXX) in Q1 Earnings?
by Zacks Equity Research
IDEXX's (IDXX) business is likely to have benefited from few cases in which pets were found to be COVID-19 positive globally.
Can IC and PI Arms Drive Boston Scientific (BSX) Q1 Earnings?
by Zacks Equity Research
Boston Scientific's (BSX) business trends in the first two months of the quarter in line with its expectations.